RECRUITINGOBSERVATIONAL
Bariatric Surgery and Pharmacokinetics of Lercanidipine
Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine
About This Trial
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on lercanidipine are investigated.
Who May Be Eligible (Plain English)
Who May Qualify:
- Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
- Being a Norwegian citizen
Who Should NOT Join This Trial:
- Having previously undergone resections in the GI-tract
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
* Being a Norwegian citizen
Exclusion Criteria:
* Having previously undergone resections in the GI-tract
Treatments Being Tested
DRUG
Lercanidipine
Patients are tested for their normal prescription lercanidipine medication
Locations (1)
St. Olavs University Hospital
Trondheim, Norway